Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma

Clinical and Experimental Allergy

Volumn 32, Issue 7, 2002, Pages 1096-1103

  Meijer, R J ^a   Postma, D S ^a   Kauffman, H F ^a   Arends, L R ^a   Koeter G H ^a   Kerstjens, H A M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Asthma; Clinical response; Corticosteroids; ECP; Eosinophils; Inflammation; Nitric oxide; Quality of life

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; FLUTICASONE PROPIONATE; METHACHOLINE; PREDNISOLONE; STEROID; CORTICOSTEROID; EOSINOPHIL GRANULE PROTEIN; NITRIC OXIDE; PLASMA PROTEIN; RIBONUCLEASE;

ACCURACY; ADULT; ARTICLE; ASTHMA; BLOOD; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SMOKING; SPUTUM; SPUTUM LEVEL; TREATMENT OUTCOME; ADOLESCENT; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PSYCHOLOGICAL ASPECT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ASTHMA; BLOOD PROTEINS; EOSINOPHILS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; MIDDLE AGE; NITRIC OXIDE; PREDNISOLONE; QUALITY OF LIFE; SUPPORT, NON-U.S. GOV'T; EOSINOPHIL GRANULE PROTEINS; HUMANS; MIDDLE AGED; RIBONUCLEASES;

EID: 0035987316     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2002.01412.x     Document Type: Article

References (44)

1. The British guidelines on asthma management. 1995 Review and positioning statement
2. New NHLBI guidelines for the diagnosis and management of asthma
3. Comparison of guidelines and self-management plans in asthma
4. Quality of life in asthma clinical trials: Comparison of salmeterol and salbutamol
5. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy in obstructive airways disease
6. Effects of fluticasone propionate on methacholine dose-response curves in nonsmoking atopic asthmatics
7. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD
8. Effects of glucocorticosteroids on inflammatory cells relevant to their therapeutic applications in asthma
9. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients
10. Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma
11. An inhaled steroid improves markers of airway inflammation in patients with mild asthma
12. Effect of low-dose beclomethasone dipropionate on asthma control and airway inflammation
13. Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal
14. Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma
15. Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro
16. Glucocorticoid-resistant asthma: Pathogenesis and clinical implications for management
17. Measuring quality of life in asthma
18. Airway responsiveness: Standardized challenge testing with pharmacological, physical, and sensitizing stimuli in adults
19. Nitric oxide measured with single-breath and tidal-breathing methods in asthma and COPD
20. Increased amount of nitric oxide in exhaled air of asthmatics
21. Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma
22. Comparison of samples collected by sputum induction and bronchoscopy from asthmatic and healthy subjects
23. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis
24. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma
25. Airway responsiveness to histamine or methacholine: Advances in measurement and interpretation
26. Comparison of two methods of collecting induced sputum in asthmatic subjects
27. Clinical significance of measuring levels of sputum and serum ECP and serum IL-5 in bronchial asthma
28. Dosage and time effects of inhaled budesonide on bronchial hyperreactivity
29. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics
30. Airways hyperresponsiveness, bronchodilator response, allergy, and smoking habit predict improvement in FEV1 during long-term inhaled corticosteroid treatment
31. Effects of budesonide and fluticasone on 24-hour plasma cortisol. A dose-response study
32. The CC chemokine receptor antagonist Met-RANTES inhibits eosinophil effector functions
33. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease
34. Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics
35. Analysis of induced sputum to examine the effects of inhaled corticosteroid on airway inflammation in children with asthma
36. Fluticasone propionate induced alterations to lung function and the immunopathology of asthma over time
37. A Comparison of oral and inhaled steroids in patients with chronic airways obstruction. Features determining response
38. Treatment of chronic asthma with prednisolone, significance of eosinophils in the sputum
39. Do sputum eosinophils and ECP relate to the severity of asthma?
40. Nitric oxide and asthmatic inflammation
41. A comparison of exhaled nitric oxide and induced sputum As markers of airway inflammation